After catching up with Zogenix management, Piper Jaffray analyst Danielle Brill says she believes Fintepla’s efficacy is superior to other available agents for Dravet Syndrome. The analyst continues to like the shares into 2019 and reiterates an Overweight rating on the name with a $72 price target. Brill expects a positive FDA panel/approval in Q3 of 2019 to drive shares higher next year. Further, she sees additional upside if labeling is favorably differentiated from competitor drugs.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.